Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of brodalumab in systemic sclerosis with moderate to severe skin thickening
jRCT2080224687Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Brodalumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started May 2019; status: completed.
02
Drugs
brodalumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2080224687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224687.